AjeetGajraMDFACP

Oncology • East Syracuse, NY

Genitourinary Oncology, Hematologic Oncology, Hospice & Palliative, Thoracic Cancer

Chief Scientific Officer, HOACNY Sr Medical Consultant, Cardinal Health

Join to view full profile

Dr. Gajra is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gajra's full profile

Already have an account?

Office
5008 Brittonfield Pkwy
East Syracuse, NY 13057
Phone+1 315-472-7504

Fax+1 315-634-5168

Summary

I am a medical oncologist with board certifications in Medical Oncology, Hematology, Palliative Medicine and Internal Medicine. My goal in the clinic is twofold:
First, to provide compassionate care to patients with cancer and blood disorders. As a life long clinical researcher, I lead the clinical research within our practice and strive to bring cancer clinical trials to our patients and community here in the Syracuse area.
My clinical areas of interest are: Thoracic (Lung ca, esophageal ca), Head & Neck, GU (prostate, kidney and bladder cancers) and Geriatric oncology.
It is my firm belief that everyone deserves the same respect and compassion as we expect for ourselves and our families.

Education & Training

SUNY Upstate Medical UniversityFellowship, Hematology and Medical Oncology, 1998 - 2001
SUNY Upstate Medical UniversityResidency, Internal Medicine, 1996 - 1998
Maulana Azad Medical CollegeClass of 1993

Certifications & Licensure

NY State Medical License 2006 - 2025
IN State Medical License 1998 - 2023
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Fellow (FACP) American College of Physicians, 2012
Anita Award for compassionate care Hospice of Central New York
Inducted Alpha Omega Alpha

Clinical Trials

Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
Active, not recruiting
Phase 3
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer Start of enrollment: 2007 May 08
Active, not recruiting
Phase 3
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Start of enrollment: 2008 Mar 01
Completed
Phase 2
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide Start of enrollment: 2008 Mar 01
Active, not recruiting
Phase 3
Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy Start of enrollment: 2008 Jun 15
Completed
Phase 3
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Start of enrollment: 2008 Apr 15
Completed
Phase 2
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2009 Jul 15
Terminated
Phase 3
Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2010 Feb 01
Terminated
Phase 3
Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects Start of enrollment: 2011 Jul 01
Terminated
Phase 2
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors Start of enrollment: 2013 Sep 20
Active, not recruiting
Phase 2
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation Start of enrollment: 2022 Nov 28
Recruiting
Phase 2
TEMPUS ARIES: A Biobank Registry Platform Study in Oncology Start of enrollment: 2024 Jun 01
Recruiting
Join now to see all

Publications & Presentations

PubMed

4 citations
Augmented intelligence to predict 30-day mortality in patients with cancer.
Ajeet Gajra, Marjorie E Zettler, Kelly A Miller, Sibel Blau, Swetha S Venkateshwaran
Future Oncology. 2021-06-30
409 citations
Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer
Arti Hurria, Supriya G. Mohile, Ajeet Gajra, Heidi D. Klepin, Hyman B. Muss
Journal of Clinical Oncology. 2016-09-27
1179 citations
Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study
Arti Hurria, Kayo Togawa, Supriya G. Mohile, Cynthia Owusu, Heidi D. Klepin
Journal of Clinical Oncology. 2011-09-01

Abstracts/Posters

Adverse Events in Elderly Hodgkin Lymphoma Patients Treated with Pembrolizumab or Nivolumab in the Real World
Ajeet Gajra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Real-World Analysis of Adverse Events Associated with CAR T-Cell Therapy Among Adults Age _65 Years
Ajeet Gajra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Utilization of Immune Checkpoint Inhibitors for Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) in Oncology Community Practices
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Perceptions of Community Hematologists/Oncologists on Barriers to Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Diffuse Large B-Cell Lymphoma
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019